EP3952840A4 - PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL BEHAVIOR COGNITIVE DISORDERS - Google Patents
PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL BEHAVIOR COGNITIVE DISORDERS Download PDFInfo
- Publication number
- EP3952840A4 EP3952840A4 EP19924315.5A EP19924315A EP3952840A4 EP 3952840 A4 EP3952840 A4 EP 3952840A4 EP 19924315 A EP19924315 A EP 19924315A EP 3952840 A4 EP3952840 A4 EP 3952840A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- methods
- pharmaceutical compositions
- cognitive disorders
- mental behavior
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000010877 cognitive disease Diseases 0.000 title 1
- 230000003340 mental effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/027293 WO2020209872A1 (en) | 2019-04-12 | 2019-04-12 | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3952840A1 EP3952840A1 (en) | 2022-02-16 |
| EP3952840A4 true EP3952840A4 (en) | 2022-11-23 |
Family
ID=72751206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19924315.5A Pending EP3952840A4 (en) | 2019-04-12 | 2019-04-12 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL BEHAVIOR COGNITIVE DISORDERS |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3952840A4 (en) |
| JP (1) | JP7365426B2 (en) |
| CN (1) | CN113939276A (en) |
| AU (1) | AU2019445048A1 (en) |
| CA (1) | CA3136633A1 (en) |
| WO (1) | WO2020209872A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
| US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
| US10966989B2 (en) | 2019-04-12 | 2021-04-06 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
| US10639314B1 (en) | 2019-04-30 | 2020-05-05 | LA PharmaTech Inc. | Method of treating Alzheimer's disease |
| US11389458B2 (en) | 2019-04-12 | 2022-07-19 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating parkinson's and huntington's disease |
| US11938139B2 (en) | 2019-04-12 | 2024-03-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders |
| US10898493B2 (en) | 2019-04-12 | 2021-01-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease |
| US11318144B2 (en) | 2019-04-12 | 2022-05-03 | LA PharmaTech Inc. | Compositions and methods for treating Alzheimer's disease and Parkinson's disease |
| AU2019443520A1 (en) * | 2019-04-30 | 2021-12-23 | La Pharma Tech Inc. | A method of treating mental, behavioral, cognitive disorders |
| US11351179B1 (en) | 2021-08-05 | 2022-06-07 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of psychiatric disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2377557T (en) * | 2004-11-24 | 2017-02-10 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| WO2014018563A2 (en) * | 2012-07-23 | 2014-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for the treatment of cancer |
| WO2018081508A1 (en) * | 2016-10-28 | 2018-05-03 | Chase Pharmaceutical Corporation | Memantine combinations and use |
| JP7198575B2 (en) * | 2017-07-11 | 2023-01-04 | キョーリンリメディオ株式会社 | Orally disintegrating tablet containing memantine hydrochloride |
-
2019
- 2019-04-12 WO PCT/US2019/027293 patent/WO2020209872A1/en not_active Ceased
- 2019-04-12 CN CN201980095322.XA patent/CN113939276A/en active Pending
- 2019-04-12 AU AU2019445048A patent/AU2019445048A1/en not_active Abandoned
- 2019-04-12 CA CA3136633A patent/CA3136633A1/en active Pending
- 2019-04-12 EP EP19924315.5A patent/EP3952840A4/en active Pending
- 2019-04-12 JP JP2021556914A patent/JP7365426B2/en active Active
Non-Patent Citations (2)
| Title |
|---|
| AIKO HATAKEYAMA ET AL: "AZELASTINE HYDROCHLORIDE ON BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS AND ACTIVITIES OF DAILY LIVING IN DEMENTIA PATIENTS", GERIATR. GERONTOL. INT,, vol. 8, 1 January 2008 (2008-01-01), pages 59 - 61, XP002798078 * |
| TARIOT PIERRE N ET AL: "MEMANTINE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER DISEASE ALREADY RECEIVING DONEPEZIL. A RANDOMIZED CONTROLLED TRIAL", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, AMERICAN MEDICAL ASSOCIATION, US, vol. 291, no. 3, 21 January 2004 (2004-01-21), pages 317 - 324, XP009075923, ISSN: 0098-7484, DOI: 10.1001/JAMA.291.3.317 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3952840A1 (en) | 2022-02-16 |
| CA3136633A1 (en) | 2020-10-15 |
| WO2020209872A1 (en) | 2020-10-15 |
| CN113939276A (en) | 2022-01-14 |
| JP7365426B2 (en) | 2023-10-19 |
| AU2019445048A1 (en) | 2021-12-02 |
| JP2022535644A (en) | 2022-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3952840A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL BEHAVIOR COGNITIVE DISORDERS | |
| EP3931189A4 (en) | AZEPINO-INDOLES AND OTHER HETEROCYCLIES FOR THE TREATMENT OF BRAIN DISEASES | |
| EP3750887C0 (en) | BIARYL DERIVATIVES AND THEIR PHARMACEUTICAL USE FOR THE TREATMENT OF PD-1/PD-L1 SIGNATURE-MEDIATED DISEASES | |
| EP3490603A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF MASP-3 FOR TREATMENT OF VARIOUS DISEASES AND DISORDERS | |
| EP3507371A4 (en) | PROCEDURES AND COMPOSITIONS AND TREATMENT OF DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | |
| EP3826666A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NRP2-ASSOCIATED DISEASES | |
| EP3969597A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATPASE-MEDIATED DISEASES | |
| EP3972691A4 (en) | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DRUG OVERDOSE | |
| EP3621593C0 (en) | Pharmaceutical compositions and methods for treating cardiovascular diseases | |
| EP3902525A4 (en) | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASES | |
| EP4008718C0 (en) | HETEROARYLAMIDOPYRIDINOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR THE PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES | |
| EP3818085A4 (en) | COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISEASES OR DISORDERS | |
| EP4384219A4 (en) | COMPOSITIONS, DOSES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | |
| EP3689875A4 (en) | USE OF TRIAZOLOPYRIMIDINE, TRIAZOLOPYRIDINE COMPOUNDS, AND COMPOSITIONS THEREOF, FOR THE TREATMENT OF PRC2-MEDIATED DISEASES | |
| EP3920898C0 (en) | Methods and compositions for the treatment of sleep apnea | |
| EP3952881A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONTACT LENS DISORDERS | |
| EP3813793A4 (en) | COMPOSITION FOR THE TREATMENT OF OCULAR HYPEREMIA AND METHODS FOR TREATMENT OF OCULAR HYPEREMIA THEREFORE | |
| EP3979996A4 (en) | METHODS AND FORMULA FOR THE TREATMENT OF VISUAL DISORDERS | |
| EP3636281A4 (en) | METHOD OF TREATMENT OF DEPRESSION AND PHARMACEUTICAL COMPOSITION | |
| EP3755319A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MUSCLE DISEASES | |
| EP3960858C0 (en) | Small RNA drug for the prevention and treatment of inflammation-related diseases and combinations thereof | |
| EP3488850A4 (en) | INNOVATIVE USE OF GZD824 AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF FOR THE TREATMENT OF DISEASES | |
| EP4058017A4 (en) | MEDICINAL FORMULATIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| EP3610879A4 (en) | COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF ALZHEIMER'S DISEASE | |
| EP3840745A4 (en) | METHODS AND COMPOSITIONS FOR MEDICATIONS FOR THE TREATMENT OF EYE DISEASES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20211111 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20221024 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/28 20060101ALI20221018BHEP Ipc: A61K 47/00 20060101ALI20221018BHEP Ipc: A61K 31/495 20060101ALI20221018BHEP Ipc: A61K 31/55 20060101ALI20221018BHEP Ipc: A61K 31/13 20060101ALI20221018BHEP Ipc: A61K 9/48 20060101ALI20221018BHEP Ipc: A61K 9/20 20060101ALI20221018BHEP Ipc: A61K 9/14 20060101ALI20221018BHEP Ipc: A61K 9/10 20060101ALI20221018BHEP Ipc: A61K 9/08 20060101AFI20221018BHEP |